Literature DB >> 33516431

Immunotherapy in Head and Neck Cancer-Ready for Prime Time or More Research Needed?

Sana D Karam1, Carryn M Anderson2, Daniel Ma3, Melvin L K Chua4, Randall J Kimple5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33516431      PMCID： PMC8597385          DOI： 10.1016/j.ijrobp.2020.11.022

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  16 in total

1.  Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.

Authors:  Ravindra Uppaluri; Katie M Campbell; Obi L Griffith; Douglas R Adkins; Ann Marie Egloff; Paul Zolkind; Zachary L Skidmore; Brian Nussenbaum; Randal C Paniello; Jason T Rich; Ryan Jackson; Patrik Pipkorn; Loren S Michel; Jessica Ley; Peter Oppelt; Gavin P Dunn; Erica K Barnell; Nicholas C Spies; Tianxiang Lin; Tiantian Li; David T Mulder; Youstina Hanna; Iulia Cirlan; Trevor J Pugh; Tenny Mudianto; Rachel Riley; Liye Zhou; Vickie Y Jo; Matthew D Stachler; Glenn J Hanna; Jason Kass; Robert Haddad; Jonathan D Schoenfeld; Evisa Gjini; Ana Lako; Wade Thorstad; Hiram A Gay; Mackenzie Daly; Scott J Rodig; Ian S Hagemann; Dorina Kallogjeri; Jay F Piccirillo; Rebecca D Chernock; Malachi Griffith
Journal:  Clin Cancer Res       Date:  2020-07-14       Impact factor: 12.531

2.  Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity.

Authors:  Paula Kroon; Elselien Frijlink; Victoria Iglesias-Guimarais; Andriy Volkov; Marit M van Buuren; Ton N Schumacher; Marcel Verheij; Jannie Borst; Inge Verbrugge
Journal:  Cancer Immunol Res       Date:  2019-02-19       Impact factor: 11.151

3.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 4.  Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.

Authors:  Sirisha L Mushti; Flora Mulkey; Shenghui Tang; Harpreet Singh; Steven J Lemery; Kirsten B Goldberg; Rajeshwari Sridhara; Patricia Keegan; Paul G Kluetz; Richard Pazdur; Marc R Theoret; Julia A Beaver
Journal:  Curr Oncol Rep       Date:  2020-08-27       Impact factor: 5.075

Review 5.  Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer.

Authors:  Stergios Doumas; Periklis G Foukas; Panagiota Economopoulou; Ioannis Kotsantis; Amanda Psyrri
Journal:  Oral Oncol       Date:  2019-12-11       Impact factor: 5.337

6.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Sean McBride; Eric Sherman; C Jillian Tsai; Shrujal Baxi; Jahan Aghalar; Juliana Eng; Wanqing Iris Zhi; Daniel McFarland; Loren Scott Michel; Robert Young; Robert Lefkowitz; Daniel Spielsinger; Zhigang Zhang; Jessica Flynn; Lara Dunn; Alan Ho; Nadeem Riaz; David Pfister; Nancy Lee
Journal:  J Clin Oncol       Date:  2020-08-21       Impact factor: 44.544

8.  MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy.

Authors:  Xiaoyu Jiang; Stephanie Dudzinski; Kathryn E Beckermann; Kirsten Young; Eliot McKinley; Oliver J McIntyre; Jeffrey C Rathmell; Junzhong Xu; John C Gore
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

9.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.

Authors:  Jonathan D Schoenfeld; Glenn J Hanna; Vickie Y Jo; Bhupendra Rawal; Yu-Hui Chen; Paul S Catalano; Ana Lako; Zoe Ciantra; Jason L Weirather; Shana Criscitiello; Adrienne Luoma; Nicole Chau; Jochen Lorch; Jason I Kass; Donald Annino; Laura Goguen; Anupam Desai; Brendan Ross; Hina J Shah; Heather A Jacene; Danielle N Margalit; Roy B Tishler; Kai W Wucherpfennig; Scott J Rodig; Ravindra Uppaluri; Robert I Haddad
Journal:  JAMA Oncol       Date:  2020-10-01       Impact factor: 31.777

10.  FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab.

Authors:  Matthew Scarpelli; Christopher Zahm; Scott Perlman; Douglas G McNeel; Robert Jeraj; Glenn Liu
Journal:  J Immunother Cancer       Date:  2019-01-30       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.